Enhancement of the HIV-1-Specific Immune Response Induced by an mRNA Vaccine through Boosting with a Poxvirus MVA Vector Expressing the Same Antigen
Authors:
- Carmen Elena GómezCarmen Elena Gómez
- Beatriz PerdigueroBPBeatriz Perdiguero
- Lorena UseroLULorena Usero
- Laura Marcos-VillarLMLaura Marcos-Villar
- Laia MirallesLMLaia Miralles
- Lorna LealLLLorna Leal
- Carlos Óscar S. SorzanoCSCarlos Óscar S. Sorzano
- Cristina Sánchez-CorzoCSCristina Sánchez-Corzo
- Montserrat PlanaMPMontserrat Plana
- Felipe GarcíaFGFelipe García
- Mariano EstebanMEMariano Esteban
Open Access
Abstract
Development of a vaccine against HIV remains a major target goal in the field. The recent success of mRNA vaccines against the coronavirus SARS-CoV-2 is pointing out a new era of vaccine designs against pathogens. Here, we have generated two types of mRNA vaccine candidates against HIV-1; one based on unmodified vectors and the other on 1-methyl-3′-pseudouridylyl modified vectors expressing a T cell multiepitopic construct including protective conserved epitopes from HIV-1 Gag, Pol and Nef proteins (referred to as RNA-TMEP and RNA-TMEPmod, respectively) and defined their biological and immunological properties in cultured cells and in mice. In cultured cells, both mRNA vectors expressed the corresponding protein, with higher levels observed in the unmodified mRNA, leading to activated macrophages with differential induction of innate immune molecules. In mice, intranodal administration of the mRNAs induced the activation of specific T cell (CD4 and CD8) responses, and the levels were markedly enhanced after a booster immunization with the poxvirus vector MVA-TMEP expressing the same antigen. This immune activation was maintained even three months later. These findings revealed a potent combined immunization regimen able to enhance the HIV-1-specific immune responses induced by an mRNA vaccine that might be applicable to human vaccination programs with mRNA and MVA vectors.Keywords
Funding Information
- Ministerio de Asuntos Económicos y Transformación Digital, Gobierno de España (SAF2015-66193-R, SAF-2017-88089-R, RTI2018-096309-B-I00)
- Spanish AIDS Research Network (RD16/0025/0002 and RD16/0025/0014-ISCIII-FEDER (RIS))
- Fondo de Investigación Sanitaria (FIS) (AC16/00051 and PI18/00699)
- Instituto de Salud Carlos III (COV20/00214; ICI20/00067)
- CERCA Programme/Generalitat de Catalunya (SGR 615 and SGR 653)
- European Commission (FP7-HEALTH-2013-INNOVATION-1 602570-2, H2020-SC1-2016-2017 (H2020-SC1-2016- RTD) Proposal: 731626-HIVACAR)
- European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie (754550)
- 'la Caixa' Foundation (ID 100010434 under the agreement LCF/PR/GN18/50310006)
This publication has 22 references indexed in Scilit:
- Preclinical evaluation of an mRNA HIV vaccine combining rationally selected antigenic sequences and adjuvant signals (HTI-TriMix)AIDS, 2017
- Intranodal Vaccination with Naked Antigen-Encoding RNA Elicits Potent Prophylactic and Therapeutic Antitumoral ImmunityCancer Research, 2010
- Insertion of Vaccinia Virus C7L Host Range Gene into NYVAC-B Genome Potentiates Immune Responses against HIV-1 AntigensPLOS ONE, 2010
- Dendritic Cell Subsets as Vectors and Targets for Improved Cancer Therapy2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- Poxvirus CD8+T-Cell Determinants and Cross-Reactivity in BALB/c MiceJournal of Virology, 2006
- Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNAImmunity, 2005
- Recombinant viruses expressing a human malaria antigen can elicit potentially protective immune CD8+responses in miceProceedings of the National Academy of Sciences, 1998
- Influenza and vaccinia viruses expressing malaria CD8+ T and B cell epitopes. Comparison of their immunogenicity and capacity to induce protective immunity.The Journal of Immunology, 1994
- Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria.Proceedings of the National Academy of Sciences, 1993